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Both the urokinase-type and tissue-type plasminogen activator can convert their - 54 kDa type-l inhibitor 
(PAI-1) to an inactive form with a lower apparent molecular mass. We have determined the amino-terminal 
amino acid sequences of human native and converted PAI-1, and isolated PAI-I cDNA and determined 
the nucleotide sequence in regions corresponding to the amino-terminus and the cleavage site. The data 
show that the conversion of the inhibitor consists of cleavage of an Arg-Met bond 33 residues from the 
carboxy-terminus, thus localizing the reactive center of the inhibitor to that position. In addition, a hetero- 
geneity was found at the amino-terminus, with a Ser-Ala-Val-His-His form and a two-residue shorter form 
(Val-His-His-) occurring in approximately equal quantities. 
Plasminogen activator Plasminogen activator inhibitor Amino acid sequence Nucleotide sequence Serpin 
1. INTRODUCTION 
Plasminogen activators are serine proteases that 
catalyze the conversion of the abundant proen- 
zyme plasminogen to the active protease plasmin 
by specific cleavage of a single peptide bond. There 
are two known types of plasminogen activators, 
the urokinase-type (u-PA) and the tissue-type (t- 
Abbreviations: PAI- 1, type- 1 plasminogen activator in- 
hibitor; PAI-2, type-2 plasminogen activator inhibitor; 
u-PA, urokinase-type plasminogen activator; t-PA, 
tissue-type plasminogen activator; PBS, 0.01 M sodium 
phosphate, pH 7.4, 0.15 M NaCl; PAGE, polyacryl- 
amide gel electrophoresis; SSC, 0.15 M NaCl, 0.015 M 
sodium citrate, pH 7.6; Denhardt’s solution, 0.02 
mg/ml Ficoll, 0.02 mg/ml polyvinylpyrrolidone, 0.02 
mg/ml bovine serum albumin; DTT, dithiothreitol; 
PTH, phenylthiohydantoin 
PA); they are products of different genes (reviews 
[1,2]). Two types of specific and fast-acting in- 
hibitors of plasminogen activators have been 
distinguished by immunochemical criteria; both in- 
hibit u-PA as well as t-PA [3-211. They may be 
designated PAI- and PAI-2, respectively. [No- 
menclature recommended by the Subcommittee on 
Fibrinolysis of the International Committee on 
Thrombosis and Hemostasis, June 8, 1986 (Kruit- 
hof, E.K.O., personal communication).] 
We previously demonstrated that incubation of 
human PAI- with catalytic amounts of u-PA or t- 
PA resulted in the conversion of the inhibitor to an 
inactive form, which, as judged from its elec- 
trophoretic mobility, had a slightly smaller Mr than 
the native form [22]. This suggests a proteolytic at- 
tack by the activators at the reactive center of 
PAI-1, similar to what has been observed with in- 
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hibitors of other serine proteases [23,24]. We now 
report amino acid sequence data of PAI-1, and 
isolation and partial sequencing of PAI- cDNA, 
localizing the site of proteolytic cleavage and iden- 
tifying an amino-terminal heterogeneity. 
2. MATERIALS AND METHODS 
PAI- was purified to apparent homogeneity 
from serum-free conditioned culture fluid of the 
human HT-1080 fibrosarcoma cell line, essentially 
as described [20]; Tris and glycine, however, were 
replaced with potassium phosphate and acetic acid 
in order to allow subsequent amino acid sequence 
analysis. Purified preparations were dialyzed ex- 
tensively against PBS. For cleavage of PAI-1, it 
was first activated with 0.1% SDS for 1 h at room 
temperature at a concentration of approx. 100 
fig/ml (see [15,22,25]); Triton X-100 was then add- 
ed to a concentration of 1070, and u-PA or t-PA to 
a concentration of 0.5 pg/ml (molar ratio 
PAI- : plasminogen activator equal to approx. 
200: 1). This mixture was incubated for 4 h at 37°C 
(see [22]). PAI- conversion by either u-PA or t- 
PA was better than 90%, as judged by SDS-PAGE 
analysis. 
For determination of amino-terminal amino 
acid sequences of native or converted PAI-1, these 
proteins were precipitated with 20% trichloro- 
acetic acid, washed with acetone and dried. The 
samples were dissolved in 1% SDS and brought to 
alkaline pH with ammonium hydroxide, or dis- 
solved in 70% trifluoroacetic acid. Approx. 1 nmol 
protein was subjected to sequence analysis. To ob- 
tain internal partial amino acid sequence data for 
generating oligonucleotide probes, PAI- was 
reduced and carboxymethylated with iodoacetic 
acid, 1:40 weight additions of Staphylococcus V8 
protease was made at 0 and 5 h, and the digestion 
was continued for a total of 24 h at 37°C. Peptides 
were separated by reversed-phase HPLC on a 
Vydac Cl8 column with a O-80% acetonitrile gra- 
dient in 0.05% trifluoroacetic acid, and their 
amino acid sequences determined. Protein sequen- 
cing was performed with Applied Biosystems 
model 470A gas-phase sequencers [26,27]. A 
39-mer oligonucleotide corresponding to a methio- 
nine-containing peptide was synthesized with an 
Applied Biosystems oligonucleotide synthesizer 
1281. 
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A cDNA library established from an SV40- 
transformed human fibroblast cell line, GM637, 
by the use of the pcD vector system [29], was 
screened with a 32P end-labelled 39-mer oligonu- 
cleotide probe (see below) by the procedure of 
Verde et al. [30], hybridizing filters in 5 x SSC, 
10 x Denhardt’s solution, 0.1% SDS, 200 pg/ml of 
yeast tRNA and 200pg/ml of salmon sperm DNA 
at 52°C for 16 h, followed by a wash in 5 x SSC, 
0.1% SDS at the same temperature. Positive clones 
were isolated, and their DNA analyzed by restric- 
tion enzyme mapping, hybridization to the syn- 
thetic oligonucleotide probe, and by nucleotide 
sequencing. Nucleotide sequencing was carried out 
by the dideoxy method [31], using restriction en- 
zyme fragmented DNA cloned into Ml3 vectors 
[32,33]. 
Poly(A)+ RNA from GM637 cells was analyzed 
by a Northern blot technique, hybridizing filters 
with the 39-mer oligonucleotide probe under the 
conditions described above. 
PAI- was identified and quantitated by reverse 
zymography [15] and ELISA (Nielsen, L.S. et al., 
in preparation). 
All reagents and enzymes were those described 
before [15,20-22,26,30,34], or of the best grade 
commercially available. 
3. RESULTS AND DISCUSSION 
Amino acid sequence analysis of five different 
native PAI- preparations showed 2 residues in 
each cycle. The analyses unambiguously identified 
the amino-terminal sequence Ser-Ala-Val-His-His- 
Pro-Pro-Ser-Tyr-Val-Ala-His-Leu-Ala-Ser-Asp- 
Phe-Gly-Val-Arg-Xaa-Phe-Gln-, accounting for 
approx. 45%, and the identical des(Ser-Ala) varie- 
ty (Val-His-His-etc.) accounting for approx. 55% 
(see fig.1). Amino acid analysis of PAI- showed 
the presence of the amino sugar glucosamine and 
thus demonstrated that it is a glycoprotein (not 
shown). 
Quantitative sequence analyses on converted 
PAI- showed, in addition to the above two se- 
quences, a third one, Met-Ala-Pro-Glu-Glu-Ile-Ile- 
Met-Asp-Arg-Pro-Phe- (fig.1). Identical results 
were obtained with conversion by u-PA (2 runs) 
and t-PA (1 run). Control incubations without u- 
PA or t-PA did not contain this sequence. Thus, 
the conversion of PAI- to an inactive form ap- 
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Fig.1. Quantitative amino acid sequence analysis of 
u-PA-converted PAI-1. For each PTH-amino acid, the 
yields are plotted as a function of the cycle number. Lys, 
Gin, Trp, Cys and Thr were absent in the first 19 cycles. 
Two samples, incubated in parallel with and without 
u-PA, as described in section 2, were compared. The 
heavy bars represent he differences between u-PA- 
treated PAI- and the incubation control which was 
identical to native PAI- (not shown). The amino- 
terminal sequence of the u-PA-released fragment 
therefore reads Met-Ala-Pro-Glu-Glu-Ile-Ile-Met-Asp- 
Arg-Pro-Phe-. The linked thin bars indicate that PAI- 
exists in two varieties which differ in length by two 
residues at the amino-terminus. The des(Ser-Ala) variety 
corresponds to the first of the linked bars (Val-His-His- 
Pro-Pro-Ser-Tyr-etc.; see text), and the longer variety to 
the second of the linked bars (Ser-Ala-Val-His-His-etc.). 
pears to consist of a proteolytic cleavage of the 
molecule. We calculated that the new amino- 
terminal sequence was present in an amount cor- 
responding to 25-30% (3 runs) of the sum of the 
two other sequences, probably reflecting only par- 
tial coprecipitation with trichloroacetic acid. 
To confirm the protein sequence data and to 
localize the cleavage site, we have isolated and se- 
quenced PAI- cDNA. An oligonucleotide 39 
bases long was synthesized on the basis of the se- 
quence of a peptide obtained by Staphylococcus 
V8 protease digestion of PAI-1. The amino-ter- 
minal amino acid sequence of the peptide was Xaa- 
Leu-Gly-Met-Lys-Asp-Met-Phe-Arg-Gln-Phe-Gln- 
Ala-Asp-, and the nucleotide sequence of the 
oligonucleotide, chosen according to human codon 
usage frequence [35], was 5 ’ -GTCAGCCTGGA- 
ACTGTCGGAACATGTCCTTCATTCCTAG-3 ’ . 
An SV40-transformed human fibroblast cell 
line, GM637 [29], was found to produce high 
amounts of PAI- by reverse zymography and 
ELISA with specific monoclonal antibodies, and 
Northern blot analysis of poly(A)+ RNA from 
these cells showed that the above 39-mer probe 
hybridized to two RNA species of approx. 3.4 and 
2.4 kb (not shown). A cDNA library established 
from the GM637 cells [29] was therefore screened 
for PAI- DNA with the probe. Positive clones 
were identified with an abundance of approx. 
1: 1000. Several positive clones were isolated. 
Restriction enzyme analysis of the inserts showed 
that all clones fell into two classes, differing in the 
5 ’ - or 3 ‘-ends. The clones with the longest inserts, 
Al and A5, were chosen for further investigation. 
The insert from clone Al was approx. 2200 and 
that from clone A5 approx. 3200 nucleotides long. 
Their restriction maps (fig.2) showed that they 
were likely to be identical, except for their 3’-end. 
This was confirmed by determination of the nu- 
cleotide sequence of portions of the DNA. No dif- 
ferences were observed in their 5 ’ -noncoding and 
their coding regions (see below), but the extreme 
3 ’ -ends of their 3 ‘-untranslated regions of 800 and 
1800 nucleotides, respectively, were different (not 
shown). However, both had typical polyadenyla- 
tion sites, this sequence being present hree times in 
tandem in A5 and only once in Al. We therefore 
suggest hat the PAI- mRNA heterogeneity may 
depend on the choice of different polyadenylation 
sites during post-transcriptional processing. 
However, alternative splicing within the 3’-un- 
ATG TGP 
Fig.2. Restriction map of PAI- cDNA, clones Al and 
A5. Restriction enzymes: t, AvaI; 7, BarnHI; f , 
BgfII; 7, EcoRI; ?, SacI. The positions of the start 
and stop codons, and the site of hybridization of the 
39-mer oligonucleotide probe are indicated. The dashed 
parts of the lines at each end of the two clones indicate 
parts of the vector, i.e. the BarnHI sites at each end are 
situated a short distance inside the vector [29]. The 
distance between the start and the stop codon is in agree- 
ment with the M, of the protein, as judged from its 
migration in SDS-PAGE [15]. 
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translated region cannot be excluded. The presence 
of two genes can be excluded by preliminary 
Southern blot analysis (not shown). 
Fig.3 shows the nucleotide sequence of the por- 
tions of the DNAs corresponding to the amino- 
and carboxy-termini of the proteins for which 
amino acid sequences were available (see above). 
In a portion containing part of the 5 ’ -untranslated 
region and part of the coding region (fig. 3A), the 
first methionine codon ATG is found at nucleotide 
146 and is preceded by a sequence which is consis- 
tent with the Kozak rule for translation initiation 
[36]. This identifies the possible start of the signal 
A 
30 60 
ACAGCTGTGTTTGGCTGCAGGGCCAAGAGCGCTGTCAAGAGACCCACACGCCCCCCTCC 
90 120 
AGCAGCTGAATTCCTGCAGCTCCGGGCAGCCGCCGCCAGAGCAGGACGACCGCC~TCGC 
150 180 
AAGGCACCTCTGAGAACTTCAGGATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGG 
MetGlnMetSerProAlaLeuThrCysLeuValLeuC 
-21 
210 240 
GCCTGACCCTTGTCTTTGGTGAAGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCC 
lyLeuTh~LeuValPheGlyGlySe+llAlaValHisHisP~~ProSe~Tyr~~Al~H 
270 
ACCTGGCCTCAGACTTCGGGGTGAGGGTGTTTCAGCAGGTGGCG 
isLeuAlaSerAspPheGlyValArgValPheGlnGlnValAl~ 
+20 
B 
GTCATAGTCTCAGCCCGCATGGCCCCCGAGGAGATCATCATGGACAGACCCTTCCTCTTT 
ValIleValSerAlaAr MetAlaProGluGluIleIleMetAspArgProPheLeuPhe 
I 
GTGGTCCGGCACAACCCCACAGGAACAGTCCTTTTCATGGGCC~GTGATGG~CCCTGA 
ValValAr~HisAsnProThrGlyThrValLeuPheHetClyGlnValMetGluPro 
ACCCTGGGGAAAGACGCCTTCATCTGGGACAAAACTGGAGATGCATCGGGAAAGAAGAAA 
CTCCGAAGAAMGAATTTTATGTTATGACTCTTTCTGAAG 
Fig.3. Nucleotide sequence of selected portions of PAL-1 
DNA, clones Al and AS, and the deduced amino acid se- 
quence of the parts corresponding to the coding region. 
(A) The 5 ‘-untranslated region and the amino terminus 
of the protein. (B) The carboxy-terminus and part of the 
3 ‘-untranslated region. The arrow indicates the site of 
cleavage of PAI- by u-PA and t-PA, as identified by 
the combination of the amino acid sequence deduced 
from the nucleotide sequence of the cDNA, and the ac- 
tual amino acid sequence determined on converted 
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PAI-1. 
peptide. We find the Ser and Val residues which we 
identified as amino-terminal amino acids of the 
two forms of the mature protein, 21 and 23 
residues downstream from that, respectively. The 
heterogeneity at the N-terminus of the mature pro- 
tein is most likely due to two possible cleavage sites 
of signal peptidases, since these appear to cleave at 
the carboxyl side of small, neutral amino acids like 
glycine or alanine [37]; these are indeed the resi- 
dues preceding the two observed amino-terminal 
amino acids of mature PAI- (fig.3A). However, 
we cannot exclude the possibility that further pro- 
cessing or degradation occurred after removal of 
the signal peptide. 
An additional sequenced DNA region covered 
the carboxy-terminal 39 amino acid residues of the 
protein, a TGA stop codon and 104 nucleotides of 
the 3’-untranslated region (fig.3B). The carboxy- 
terminal amino acid sequence derived from the 
DNA sequence overlaps and confirms the amino 
acid sequence identified as the amino-terminal end 
of the peptide released by cleavage with u-PA or t- 
PA (cf. figs 1 and 3B). The combination of the 
results from protein and DNA sequencing iden- 
tifies the cleavage site at an Arg-Met bond 33 
residues before the carboxy-terminus and thus 
localizes the active center of PAI- to that position 
123,241. The molecular mass of the released frag- 
ment is 3804 kDa. 
The presence of an arginine residue on the car- 
boxy1 side of the bond cleaved in PAI- matches 
the substrate specificity of the activators, since 
both t-PA and u-PA cleave an Arg-Val bond in 
plasminogen. This is in good agreement with 
findings with the other inhibitors of serine pro- 
teases (serpins), since their inhibitory specificity is 
in each case primarily defined by a single amino 
acid, Pi, at the reactive center of the molecule 
(table 1). The inhibitor is thought to trap the pro- 
teases by presenting its reactive center as an ideal 
substrate, the Pi residue acting as bait for the ap- 
propriate serine protease. There is formation of a 
tightly bound enzyme-inhibitor complex, in which 
the acyl bond of Pi is being hydrolyzed. Cleaved 
inhibitor may subsequently be released from the 
complex (reviews [23,24]). The present data in- 
dicate that PAI- is an Argserpin, according to the 
terminology of Carrel1 and Travis [24]. 
There are no previous reports on direct amino 
acid sequence determination on human PAI-1. 
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Table 1 
Comparison of the site of proteolytic leavage of PAI- by u-PA and t-PA 
with the reactive centers of a variety of serpins and with the cleavage site of 
plasminogen 
Inhibitor or Protease Residues at reactive center or cleavage 
substrate site 
P2 PI Pi Pi Pi P4 
cur-Antitrypsin 
1411 elastase Pro Met Ser Ile Pro Pro 
QI-Antichymo- 
trypsin [42] chymase Leu Leu Ser Ala Leu Val 
Mouse con- 
trapsin [43] trypsin Arg Lys Ala Ile Leu Pro 
Cl-inhibitor 
[44,451 complement Ala Arg Thr Leu Leu Val 
component C 1 
Antithrombin 
[46-481 thrombin Gly Arg Ser Leu Asn Pro 
PAI- u-PA, t-PA Ala Arg Met Ala Pro Glu 
Plasminogen 
149,501 u-PA, t-PA Gly Arg Val Val Gly Gly 
The designation of the residues is as proposed by Schechter and Berger [Sl]. 
The PI-P{ bond is cleaved by the indicated proteases 
December 1986 
Our data are, however, in good agreement with 
recently reported data on PAI- cDNA clones 
isolated from other sources [38-401. The amino 
acid sequences presented here completely coincide 
with the data in those reports, with the exception 
of the threonine residue at position -7 in the 
signal peptide which was found to be an alanine 
residue in the other studies [39,40], and the lysine 
residue at position 5 of the peptide used as a basis 
for the oligonucleotide probe, which was found to 
be a threonine residue in the other studies [38-401. 
It is noteworthy that the site of cleavage with u-PA 
and t-PA demonstrated in this paper is identical to 
that predicted by Ny et al. [38] on the basis of 
analogy with other serpins. 
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